163 related articles for article (PubMed ID: 14575518)
1. The pharmacogenetics of immunosuppression for organ transplantation: a route to individualization of drug administration.
Fredericks S; Holt DW; MacPhee IA
Am J Pharmacogenomics; 2003; 3(5):291-301. PubMed ID: 14575518
[TBL] [Abstract][Full Text] [Related]
2. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.
Staatz CE; Goodman LK; Tett SE
Clin Pharmacokinet; 2010 Apr; 49(4):207-21. PubMed ID: 20214406
[TBL] [Abstract][Full Text] [Related]
3. The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation.
Hesselink DA; Bouamar R; Elens L; van Schaik RH; van Gelder T
Clin Pharmacokinet; 2014 Feb; 53(2):123-39. PubMed ID: 24249597
[TBL] [Abstract][Full Text] [Related]
4. Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea.
Jun KR; Lee W; Jang MS; Chun S; Song GW; Park KT; Lee SG; Han DJ; Kang C; Cho DY; Kim JQ; Min WK
Transplantation; 2009 Apr; 87(8):1225-31. PubMed ID: 19384171
[TBL] [Abstract][Full Text] [Related]
5. Genetic factors for individual administration of immunosuppressants in organ transplantation.
Yu SF; Wu LH; Zheng SS
Hepatobiliary Pancreat Dis Int; 2006 Aug; 5(3):337-44. PubMed ID: 16911928
[TBL] [Abstract][Full Text] [Related]
6. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients.
Haufroid V; Mourad M; Van Kerckhove V; Wawrzyniak J; De Meyer M; Eddour DC; Malaise J; Lison D; Squifflet JP; Wallemacq P
Pharmacogenetics; 2004 Mar; 14(3):147-54. PubMed ID: 15167702
[TBL] [Abstract][Full Text] [Related]
7. Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients.
Shi Y; Li Y; Tang J; Zhang J; Zou Y; Cai B; Wang L
Gene; 2013 Jan; 512(2):226-31. PubMed ID: 23107770
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetics of calcineurin inhibitors in renal transplantation.
Coto E; Tavira B
Transplantation; 2009 Aug; 88(3 Suppl):S62-7. PubMed ID: 19667964
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetics of immunosuppressive drugs: prospect of individual therapy for transplant patients.
Ekbal NJ; Holt DW; Macphee IA
Pharmacogenomics; 2008 May; 9(5):585-96. PubMed ID: 18466104
[TBL] [Abstract][Full Text] [Related]
10. Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation.
Zhang X; Liu ZH; Zheng JM; Chen ZH; Tang Z; Chen JS; Li LS
Clin Transplant; 2005 Oct; 19(5):638-43. PubMed ID: 16146556
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetics in transplant patients: can it predict pharmacokinetics and pharmacodynamics?
Burckart GJ; Liu XI
Ther Drug Monit; 2006 Feb; 28(1):23-30. PubMed ID: 16418689
[TBL] [Abstract][Full Text] [Related]
12. Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients.
Roy JN; Barama A; Poirier C; Vinet B; Roger M
Pharmacogenet Genomics; 2006 Sep; 16(9):659-65. PubMed ID: 16906020
[TBL] [Abstract][Full Text] [Related]
13. Does pharmacogenetics have the potential to allow the individualisation of immunosuppressive drug dosing in organ transplantation?
MacPhee IA; Fredericks S; Holt DW
Expert Opin Pharmacother; 2005 Dec; 6(15):2593-605. PubMed ID: 16316299
[TBL] [Abstract][Full Text] [Related]
14. Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation.
Niioka T; Satoh S; Kagaya H; Numakura K; Inoue T; Saito M; Narita S; Tsuchiya N; Habuchi T; Miura M
Transplantation; 2012 Nov; 94(10):1013-9. PubMed ID: 23073468
[TBL] [Abstract][Full Text] [Related]
15. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients.
Fukudo M; Yano I; Yoshimura A; Masuda S; Uesugi M; Hosohata K; Katsura T; Ogura Y; Oike F; Takada Y; Uemoto S; Inui K
Pharmacogenet Genomics; 2008 May; 18(5):413-23. PubMed ID: 18408564
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations.
Tang JT; Andrews LM; van Gelder T; Shi YY; van Schaik RH; Wang LL; Hesselink DA
Expert Opin Drug Metab Toxicol; 2016 May; 12(5):555-65. PubMed ID: 27010623
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetics of tacrolimus after renal transplantation: analysis of polymorphisms in genes encoding 16 drug metabolizing enzymes.
Tavira B; Coto E; Díaz-Corte C; Ortega F; Arias M; Torres A; Díaz JM; Selgas R; López-Larrea C; Campistol JM; Alvarez V;
Clin Chem Lab Med; 2011 May; 49(5):825-33. PubMed ID: 21480817
[TBL] [Abstract][Full Text] [Related]
18. Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients.
Quteineh L; Verstuyft C; Furlan V; Durrbach A; Letierce A; Ferlicot S; Taburet AM; Charpentier B; Becquemont L
Basic Clin Pharmacol Toxicol; 2008 Dec; 103(6):546-52. PubMed ID: 19067682
[TBL] [Abstract][Full Text] [Related]
19. An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients.
Masuda S; Inui K
Pharmacol Ther; 2006 Oct; 112(1):184-98. PubMed ID: 16759707
[TBL] [Abstract][Full Text] [Related]
20. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.
Mouly SJ; Matheny C; Paine MF; Smith G; Lamba J; Lamba V; Pusek SN; Schuetz EG; Stewart PW; Watkins PB
Clin Pharmacol Ther; 2005 Dec; 78(6):605-18. PubMed ID: 16338276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
